Correction to: Clinical and Translational Oncology https://doi.org/10.1007/s12094-023-03216-3
In Table 3 of this article, for the point "Second-line treatment in ES-SCLC", the statement "At the time of writing guideline document, lurbinectedin is FDA and EMA approved but not authorized in Spain" was incorrect but it should have been "At the time of writing guideline document, lurbinectedin is FDA approved, has granted orphan drug designation by the EMA, but not authorized in Spain." The corrected Table 3 is provided below.
The Acknowledgments and Conflict of interest sections were missing from this article and should have read as follows.
Acknowledgments
The authors thank Enriqueta Felip y Javier de Castro for their review and validation of the levels of evidence and grades of recommendation in this guideline.
Conflict of interest
RGC reports Advisory boards, Consultancy and Speaker honoraria from MSD, BMS, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takea and Amgen. IS reports Advisory Board from Roche, Novartis, Boehringer Ingelheim, Takeda and Sanofi; Speaker from Roche, MSD, Pfizer, BMS and AstraZeneca; Grant from Roche, Takeda, Pfizer, BMS and AstraZeneca; Non-financial Support from Member of GECP. EA reports Advisory Board, Speakerand Grant from Roche; Advisory Board and Speaker from Astra Zeneca and BMS; Advisory Board, Speaker and Non-financial Support from Takeda; Advisory Board from Lilly and Boehringer-Ingelheim; Speaker from MSD, Merck, Thermo Fisher Scientific and Guardant Health; Speaker and- Non-financial Support from Pfizer. AI reports Advisory Board and Speaker from Roche, AstraZeneca and Sanofi; Speaker from Takeda and BMS. OJJV reports Advisory Board and Speaker from BMS and Janssen; Speker from Roche; Advisory Board, Speaker and Other from AstraZeneca, Takeda and Janssen; Advisory Board from Lilly. NR reports Advisory Board, Speaker and- Other from MSD; Advisory Board and Speaker from AstraZeneca, Takeda, Amgen, Lilly, Sanofi, Roche and Janssen. JZ reports Speaker, Grant and Personal Feels from BMS and AstraZencea; Advisory Board and Personal Feels from Sanofi; Speaker from MSD; Grant and Personal Feels from Roche; Speaker and Personal Feels from Pfizer; Advisory Board from Novartis and Speaker from NanoString. MD reports Advisory Board and Speaker from AatraZeneca, Pfizer and Takeda; Speaker from BMS, MSD and Roche; Advisory Board from Janssen and Sanofi. TM and PCC have nothing to disclose.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
García-Campelo, R., Sullivan, I., Arriola, E. et al. Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clin Transl Oncol 25, 2760–2762 (2023). https://doi.org/10.1007/s12094-023-03290-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-023-03290-7